For ovarian cancer patients, despite the relatively poorer prognoses associated with immune checkpoint inhibitor use, an encouraging observation is that polyclonal IgA antibodies, formed through humoral immunity, bind to the ubiquitously expressed polymeric IgA receptor on ovarian cancer cells. The gene discussed is CD79A; the disease is ovarian carcinoma.